Public Employees Retirement System of Ohio lowered its position in ABIOMED, Inc. (NASDAQ:ABMD) by 0.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,536 shares of the medical equipment provider’s stock after selling 175 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in ABIOMED were worth $6,677,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ABMD. Nomura Holdings Inc. lifted its holdings in shares of ABIOMED by 95.5% in the 2nd quarter. Nomura Holdings Inc. now owns 7,709 shares of the medical equipment provider’s stock worth $2,043,000 after buying an additional 3,765 shares during the period. Bessemer Group Inc. raised its holdings in shares of ABIOMED by 132,163.4% in the second quarter. Bessemer Group Inc. now owns 148,135 shares of the medical equipment provider’s stock valued at $38,588,000 after acquiring an additional 148,023 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of ABIOMED by 17,845.5% in the second quarter. Nuveen Asset Management LLC now owns 197,759 shares of the medical equipment provider’s stock valued at $51,514,000 after acquiring an additional 196,657 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of ABIOMED by 2.1% in the second quarter. CIBC Asset Management Inc now owns 4,093 shares of the medical equipment provider’s stock valued at $1,066,000 after acquiring an additional 85 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in ABIOMED by 13.3% in the third quarter. SG Americas Securities LLC now owns 8,144 shares of the medical equipment provider’s stock worth $1,449,000 after acquiring an additional 958 shares during the period. 90.68% of the stock is currently owned by institutional investors.

Several brokerages have issued reports on ABMD. BidaskClub upgraded shares of ABIOMED from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. TheStreet lowered shares of ABIOMED from a “b-” rating to a “c+” rating in a report on Thursday, August 22nd. ValuEngine upgraded shares of ABIOMED from a “sell” rating to a “hold” rating in a report on Wednesday, September 4th. Leerink Swann upped their price target on shares of ABIOMED from $195.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, Raymond James downgraded shares of ABIOMED from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 29th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $301.20.

Shares of ABMD stock opened at $192.22 on Tuesday. The stock’s fifty day moving average price is $195.50 and its 200 day moving average price is $218.46. ABIOMED, Inc. has a 1-year low of $155.02 and a 1-year high of $364.31. The company has a market cap of $8.86 billion, a price-to-earnings ratio of 53.39, a price-to-earnings-growth ratio of 1.72 and a beta of 0.32.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, October 31st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.10. ABIOMED had a return on equity of 19.89% and a net margin of 26.92%. The company had revenue of $204.97 million during the quarter, compared to analysts’ expectations of $206.45 million. During the same period last year, the business posted $1.09 earnings per share. The firm’s revenue was up 12.8% compared to the same quarter last year. Sell-side analysts predict that ABIOMED, Inc. will post 4.32 EPS for the current year.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.